When was Skyhawk Therapeutics founded?

Skyhawk Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Skyhawk Therapeutics located?

Skyhawk Therapeutics is headquartered in Waltham, United States.

Who is the current CEO of Skyhawk Therapeutics?

Friedrich Metzger of Skyhawk Therapeutics.

How many employees does Skyhawk Therapeutics have?

As of Aug 31, 2026, the latest employee count at Skyhawk Therapeutics is 88.

Is Skyhawk Therapeutics a funded company?

Skyhawk Therapeutics is a funded company, having raised a total of $181M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 23, 2018.

When was the latest funding round of Skyhawk Therapeutics?

Skyhawk Therapeutics' latest funding was a $***** Series B round on Sep 14, 2021, with participation from 1 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.1B in funding in 2026 to date.

Where does Skyhawk Therapeutics rank among its competitors?

Skyhawk Therapeutics ranks 91st amongst 3460 active competitors, of which 1161 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Skyhawk Therapeutics?

Skyhawk Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Skyhawk Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Skyhawk Therapeutics is a series B company based in Waltham (United States), founded in 2017 by Friedrich Metzger. It operates as a Developer of RNA-modifying drug candidates for the treatment of multiple disorders. Skyhawk Therapeutics has raised $181M in funding from investors like Alexandria, Fidelity Investments and Disney. The company has 3460 active competitors, including 1161 funded and 801 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of RNA-modifying drug candidates for the treatment of multiple disorders. The company is developing RNA-targeting small molecule for Huntington's Disease, SKY-0515. It also, accelerates building RNA targeting small molecules across a range of fields including neurology, oncology and fibrotic diseases.

Website: www.skyhawktx.com/
Social
Email ID: *****@skyhawktx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Waltham, United States

Stage

Series B

Total Funding

$181M in 3 rounds

Latest Funding Round

Series B, Sep 14, 2021, $*****

Investors

Alexandria & 10 more

Ranked

91^st among 3460 active competitors

Employee Count

88 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3119 more

View Skyhawk Therapeutics' full profile

Skyhawk Therapeutics has raised a total funding of $181M over 3 rounds. Its first funding round was on Jan 23, 2018. Its latest funding round was a Series B round on Sep 14, 2021 for $*****. 1 investor participated in its latest round. Skyhawk Therapeutics has 11 institutional investors.

Here is the list of recent funding rounds of Skyhawk Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 14, 2021	5970170	Series B	4626757	8591946	2040720	7155507
Jun 26, 2018	7853690	Series A	5557778	3603613	7191258	7707579
Jan 23, 2018	7017635	Seed	4416228	9213142	Disney & 3 more	4060716

Access funding benchmarks and valuations. Sign up today!

View details of Skyhawk Therapeutics's funding rounds and investors

The founders of Skyhawk Therapeutics is Friedrich Metzger.

Here are the details of Skyhawk Therapeutics' key team members:

Friedrich Metzger: Co-Founder & CEO of Skyhawk Therapeutics.
Contact Info: 1 email address

View details of Skyhawk Therapeutics's Founder profiles and Board Members

Skyhawk Therapeutics' employee count trend

Skyhawk Therapeutics has 88 employees as of Aug 26. Here is Skyhawk Therapeutics's employee count trend over the years:

Employee count trend for Skyhawk Therapeutics

Uncover Skyhawk Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Skyhawk Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Skyhawk Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
91st	Skyhawk Therapeutics 2017, Waltham (United States), Series B	Developer of RNA-modifying drug candidates for the treatment of multiple disorders	$181M	Fidelity Investments, Acks & 9 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Skyhawk Therapeutics's competitors? Click here to see the top ones

Skyhawk Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Skyhawk Therapeutics's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Skyhawk Therapeutics

Media has covered Skyhawk Therapeutics for a total of 10 events in the last 1 year, 6 of them have been about company updates and 1 about people movement.